Physician profile
Grigory Horonenko
NPI 1356394035
$11,342.49
in general payments reported to CMS, 2019-2025
39 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,190 · 2021: $1,872 · 2022: $2,124 · 2023: $2,104 · 2024: $1,619 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,125 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.20 |
| Education | $333.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,365.96 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Electromed, INC. | $972.70 | 2019-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $962.59 | 2019-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $943.73 | 2019-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $899.48 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.58 | 2019-2025 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $591.18 | 2020-2025 | Dupixent |
| Genentech USA, INC. | $564.07 | 2019-2021 | |
| Genzyme Corporation | $493.00 | 2019-2025 | |
| United Therapeutics Corporation | $476.64 | 2019-2025 | Tyvaso, Tyvaso |
| Abiomed | $455.65 | 2023-2024 | Impella |
| Baxter Healthcare | $314.32 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $245.51 | 2019-2025 | (Di7) Home Pi Undivided, Vest Therapy Und, (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $225.36 | 2020-2024 | Glassia |
| Mylan Specialty L.P. | $198.45 | 2019-2024 | Yupelri |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigory Horonenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.